Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Preliminary Efficacy, Immunogenicity and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

NCT05331300 is registered in ClinicalTrials.gov with Lassen Therapeutics 1 PTY LTD as lead sponsor.

NCT NCT05331300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05331300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Preliminary Efficacy, Immunogenicity and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
Lead sponsor
Lassen Therapeutics 1 PTY LTD
Phase
Phase 1/2
Overall status
Completed
Start date
June 6, 2022
Completion date
November 27, 2024
Enrollment
75 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary fibrosis, thyroid eye disease